A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer
Open Access
- 1 January 2020
- journal article
- research article
- Published by SAGE Publications in Integrative Cancer Therapies
- Vol. 19
Abstract
Background: This is a retrospective study to examine the effect of chemotherapy with or without intravenous vitamin C (IVC) on women with advanced triple-negative breast cancer (TNBC). Methods: From 2008 to 2016, a total of 113 patients with pathologically confirmed TNBC at Clifford Hospital were evaluated, and 70 patients were matched and divided into IVC (treatment group) and non-IVC groups (control group). The match was according to age, menopausal status, and metastatic sites. In the control group, 35 patients received gemcitabine and carboplatin. In the treatment group, 35 patients received the same chemotherapy plus IVC. Results: Baseline characteristics were not significantly different between the 2 groups. According to the criteria of RECIST 1.1 (Response Evaluation Criteria in Solid Tumors), enhanced computed tomography scan was compared after 2 cycles of chemotherapy. In the treatment group, 2/35 cases had a complete remission (CR), 15/35 cases had partial remission (PR), and 13/35 cases had stable disease (SD). The response rate was 48.6%. In the control group, there were no CR cases, 14/35 cases had PR, 14/35 cases had SD, and the response rate was 40.0% (P > .05). The median progression-free survival time and median overall survival time was 7 months (95% confidence interval [CI] =1.5-28.5 months) and 27 months (95% CI = 4-40 months) in the treatment group compared with 4.5 months (95% CI = 1.5-8 months) and 18 months (95% CI = 3-26 months) in the control group (P < .05). All patients experienced diverse reactions in the gastrointestinal tract and myelosuppression. The incidence of adverse reactions in the treatment group was significantly lower than that of the control group (P < .05). Conclusion: IVC may have an effect on improving the prognosis of patients with advanced TNBC.Keywords
Funding Information
- Traditional Chinese Medicine Bureau of Guangdong Province (20192121)
- Science, Commerce and Information Bureau if Panyu (2018-Z04-05)
This publication has 26 references indexed in Scilit:
- The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemiaLeukemia Research, 2018
- The role of vitamin C in the treatment of pain: new insightsJournal of Translational Medicine, 2017
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- The Effect of Intravenous Vitamin C on Cancer- and Chemotherapy-Related Fatigue and Quality of LifeFrontiers in Oncology, 2014
- Phase I Clinical Trial of Intravenous L-ascorbic Acid Following Salvage Chemotherapy for Relapsed B-cell non-Hodgkin's Lymphoma.2014
- High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of ChemotherapyScience Translational Medicine, 2014
- Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancerCancer Chemotherapy and Pharmacology, 2013
- Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissuesProceedings of the National Academy of Sciences of the United States of America, 2005
- Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs.1982
- Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer.Proceedings of the National Academy of Sciences, 1976